73 results about "Sedation" patented technology

The invention relates to a painless gastrointestinal endoscope self-adaptive drug delivery method and system based on multi-source physiological signal fusion, and belongs to the technical field of medical artificial intelligence and automatic control. An artificial intelligence model is utilized to deeply extract features and quantitatively evaluate the sedation-analgesia level of a patient, a pharmacokinetics-pharmacodynamics model constructed by a big data platform is utilized to dynamically predict the drug effect according to the individual features and real-time state of the patient, and the anesthetic infusion rate is automatically and accurately adjusted through a closed-loop control algorithm, so that the patient can be accurately infused. Personalization and self-adaption of drug delivery are achieved, an independent safety monitoring mechanism is set, and real-time intervention is conducted on risk events such as respiratory depression. The problems that traditional anesthesia depends on artificial experience, single parameter monitoring is not comprehensive and individualized dynamic adjustment is lacked can be effectively solved, and the safety, comfort and medical efficiency of painless gastrointestinal endoscopy are remarkably improved.

The invention relates to the technical field of intelligent anesthesia precise regulation and control, and discloses an anesthetic dosage optimization method based on artificial intelligence. According to the method, a dynamic treatment interval is constructed, and the boundary of the dynamic treatment interval is adaptively adjusted according to the real-time sedation depth and the nociceptive stimulation level. And in the interval, performing pattern recognition on the continuous electroencephalogram signals and the hemodynamic parameters, and marking abnormal events deviating from a standard anesthesia state. And establishing a correlation network of the drug effect chamber concentration and the abnormal events, and generating a virtual drug response curve for predicting the trend of the abnormal events under different doses. Whether dose strategy reconstruction is started or not is determined by comparing the goodness of fit between the prediction curve and the actual physiological trajectory. During reconstruction, contribution weights of historical drug infusion points to abnormal events are backtracked and analyzed, and adjustment coefficients are distributed and integrated into a new infusion sequence. According to the invention, individualization and self-adaptive optimization of anesthesia administration are realized, and the accuracy and safety of anesthesia depth control are improved.

The invention relates to the technical field of medical equipment monitoring, in particular to an intelligent anesthesia atomization equipment state monitoring method and system. The method comprises the following steps: firstly, collecting atomization flow, particle size distribution, motor vibration frequency, liquid medicine temperature and pipeline pressure, and constructing an equipment state feature set; synchronously collecting electroencephalogram signals of a patient and constructing electroencephalogram state vectors; inputting the feature set into a support vector machine model to identify the running state of the equipment, and judging whether abnormity exists or not; when the equipment state is normal, an atomization efficiency attenuation equation is constructed based on continuous data, and the future efficiency trend is predicted; the prediction result and the electroencephalogram state are input into an anesthesia depth index dynamic balance model, and the adaptability of atomization output to the sedation reaction of the patient is evaluated; and when the efficiency attenuation rate is too high or the dynamic error exceeds a threshold value, generating a prompt signal and uploading the prompt signal to a remote platform. According to the invention, equipment state monitoring, efficiency prediction and neural feedback linkage control are realized, and intraoperative safety and postoperative evaluation precision are improved.

The invention discloses a sedation depth monitoring method based on a graph convolutional neural network, and relates to the technical field of sedation monitoring, and the method comprises the steps: collecting a multi-source biomarker of a patient, carrying out the filtering and artifact removal of an electroencephalogram signal, and generating preprocessed electroencephalogram data; performing attention pooling processing on the node-level feature tensor, calculating a sedation depth index, and generating a pain interference factor according to a connection edge weight of the dynamic function connection graph; and when the pain interference factor exceeds a preset pain threshold value and the sedation depth index meets a preset condition, generating a sedation optimization instruction, and when the virtual pharmacokinetic node displays metabolic abnormality, generating an infusion rate adjustment instruction. According to the method, through a dynamic function connection diagram construction link, the time-varying intensity of the skin conductance reaction signal and the rugosa electromyographic signal is used as a dynamic weight, and accurate quantification of the pain-sedation coupling effect is achieved.

The invention provides a heterocyclic compound and a pharmaceutical composition and application thereof, and belongs to the technical field of pharmaceutical chemistry. The series of heterocyclic compounds prepared by the invention have efficient sedative, hypnotic and / or anesthetic effects, can control the state of epilepsy, also have an analgesic effect, and have great significance for clinically preparing drugs with the analgesic effect and drugs with anesthetic, sedative, hypnotic and / or capable of controlling the state of epilepsy. The invention provides a new choice for the medicine which has the effects of anesthesia, sedation and hypnosis and / or can control epilepsy persistence and also has an analgesic effect.

The invention discloses a synthesis method of helicid, and relates to the technical field of compound synthesis, glucose is taken as an initial raw material, allose is obtained through a series of reactions, pentaacetyl allose is prepared from allose through acetylation reaction, tetraacetyl alloside is prepared through selective deacetylation reaction, substitution reaction and nucleophilic substitution reaction, and the helicid is synthesized through a one-step method. And finally, carrying out a deacetylation reaction on the tetraacetyl alloside to prepare helicid. Helicid has the effects of calming, sleeping, easing pain and resisting inflammation, and can be applied to preparation of medicaments with corresponding effects. The preparation method of the helicid provided by the invention is simple to operate, can be used for large-scale industrial production, and overcomes the defect of insufficient yield of naturally extracted helicid.

Methods and compositions are provided for treating individuals exhibiting opioid withdrawal symptoms with opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of opioid withdrawal symptoms, including respiratory depression, sedation, and hypotension. Methods and compositions are also provided for treating stimulant overdose with a benzodiazepine and beta-adrenergic blocking agent. Methods and compositions are also provided for treating concurrent stimulant and opioid overdose comprising administering to a patient in need thereof a benzodiazepine and an opioid antagonist. Methods and compositions are also provided for treating individuals exhibiting opioid withdrawal symptoms or prophy tactically treating individuals for opioid withdrawal symptoms from opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of withdrawal, including respiratory depression, sedation, and hypotension.

This disclosure relates to systems and methods for monitoring sedated patients that are receiving supplemental oxygen flows. A method of monitoring a patient's breathing while sedated includes identifying an end expiratory pause in the patient's breathing pattern and obtaining a first respiratory signal corresponding to a nasal pressure of a patient. The method may also include delivering a pulse of high-flow oxygen during the end expiratory pause at a rate of about 30 liters-per-minute (L / min) and delivering the pulse of high-flow oxygen during the end expiratory pause for less than 0.5 seconds. The method may further include measuring a peak nasal pressure and a peak oxygen flow and synthesizing a second respiratory signal. The second respiratory signal may correspond to the peak nasal pressure and the peak oxygen flow, and may be normalized for the patient. The method may additionally include determining the patient's breathing pattern, rate, or frequency.

This invention provides a novel GABA structure with better efficacy, reduced side effects, and greater safety for clinical use. A This invention relates to receptor agonists, specifically a phenol derivative, its preparation method, and its use in the central nervous system. The phenol derivative provided by this invention offers more and better drug options for inducing or maintaining anesthesia in animals or humans, promoting sedation and hypnosis, and treating and / or preventing anxiety, nausea, vomiting, migraines, seizures, epilepsy, neurodegenerative diseases, and other central nervous system-related disorders.

The invention discloses a critical patient rehabilitation evaluation system based on artificial intelligence, particularly relates to the technical field of medical information and intelligent rehabilitation evaluation, and is used for solving the problems that in an intensive care unit, multi-source data are not synchronous, nursing and treatment events are often caused, sedation and ventilation fluctuation pollution is caused, and the problem of serious illness is solved. And thus, the problem of distortion in judgment of which level cannot move nowadays and can move to can be solved. A unified time base is established through three types of anchor points of nursing, body position and cardiopulmonary rhythm, passivity and autonomy are judged in an influence time period, and the passivity is deducted and reserved; and then sedation, circulation, respiratory support and medication are compiled into safety budget with delay, linkage evidence quantity and uncertainty adjustment release rhythm, and degradation and rollback are triggered by an anti-fact track of margin segmentation, so that an executable prescription of'activity, reachable grade and reason 'is output beside a bed, event pollution and physiological fluctuation are inhibited, and the aim of preventing and treating the patient is fulfilled. And maloperation and missed operation are reduced.

Sedation device. The sedation device includes: a housing; the housing having a ventilator chamber and a juxtaposed vaporizer chamber; a filter installed between the ventilator chamber and the vaporizer chamber, forming a common breathable partition wall; the ventilator chamber having an inlet; the vaporizer chamber having an outlet for connection to a patient's breathing tube; and an vaporizer installed within the vaporizer chamber, wherein the inlet is positioned to guide air through the surface of the filter in the ventilator chamber and has an air guide ramp angled relative to the inlet and flared outward away from the inlet to guide incoming air inward from the inlet toward the filter and outward from the inlet through the surface of the filter; an elongated air distribution fin is installed on the outer wall of the ventilator chamber, aligned with the inlet at the inner end of the air guide ramp and extending away from the air guide ramp; the air distribution fin is perpendicular to the outer wall and located at the center of the outer wall, aligned with the inlet; the air distribution fin has a sharp leading edge facing the inlet.

Pharmaceutical combinations of etomidate derivatives and propofol and pharmaceutical compositions thereof for use in anesthesia, sedation and / or hypnosis of animals or humans. The pharmaceutical composition of the etomidate derivative and the propofol or the pharmaceutical composition of the etomidate derivative and the propofol shows an excellent synergistic effect compared with independent administration and combined administration.

A pharmaceutical combination of an etomidate derivative and ciprofol, and a pharmaceutical composition comprising the etomidate derivative and ciprofol. Use of the pharmaceutical combination or the pharmaceutical composition in anesthesia, sedation, and / or hypnosis of animals or humans. Compared to the administration of the etomidate derivative or ciprofol alone and the combined administration of etomidate and ciprofol, the pharmaceutical combination or the pharmaceutical composition shows an excellent synergistic effect, significantly improving the recovery time after anesthesia withdrawal, etc.

A method for operating a hemorrhoid treatment device includes coupling a hemorrhoid treatment device to a computing device with a cable. A probe electrode is coupled to the hemorrhoid treatment device. A grounding pad is placed in contact with a patient to be treated for hemorrhoids. The grounding pad is to be coupled to the hemorrhoid treatment device. Anesthesia or sedation is provided to patient. The method includes setting a level of current to be applied by the hemorrhoid treatment device, with the level of current exceeding a level that causes discomfort to the patient. The hemorrhoid treatment device is operated to deliver an output voltage to the probe electrode, with the probe electrode to contact the hemorrhoid being treated, and adjust the output voltage to compensate for fluctuations in body resistance of the patient so that the set level of current being delivered to the hemorrhoid is consistent.

The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.

Methods of sedation using active peptides are provided, as are compositions comprising the peptides and uses of the peptides.

The present invention relates to new liquid compositions, formulated to keep menthol as an anesthetic agent stable in the liquid composition, and to the use of this composition. The composition is for sedation or anesthesia of fish in different handling procedures including in fish breeding and harvesting facilities. The invention relates to liquid compositions for anesthesia of fish, and particularly to compositions comprising a menthol as an anesthetic agent, and wherein the menthol is formulated in a liquid vehicle comprising propylene glycol. Furthermore, the invention relates to a method for anesthesia of fish, using the liquid composition comprising a menthol.

A device 1 for providing pain relief and / or sedation to a patient, the device comprising a handset 301 and a patient delivery interface 10 e.g. mask, the handset having a patient-controlled initiator

Described herein is a method of administering injectable cetirizine or levocetirizine to treat acute urticaria, with or without concomitant angioedema, without life-threatening airway swelling by intravenously injecting a human patient within minutes to hours of developing acute urticaria in an emergency department or clinic with a therapeutically effective amount of an injectable cetirizine or levocetirizine composition. In the method, the injectable cetirizine or levocetirizine is the only treatment administered in the emergency department or clinic. The method can include determining, by the patient, a patient rated pruritus severity score at a 1 hour assessment, and optionally at a 2 hours assessment, and a physician discharging the human patient after 1.7±0.9 hours in the emergency department or clinic, wherein the human patient has a patient rated pruritus severity score reduction of at least 1 unit and baseline sedation at the time of discharge.

1. Name of the product in this design: Oropharyngeal ventilation tube. 2. Purpose of this design: To provide comfortable diagnosis and treatment for painless endoscopy such as painless gastroscopy, colonoscopy, and bronchoscopy, as well as an airway management tool during sedation and anesthesia for painless egg retrieval, superficial or minor surgeries. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the key design points: Design 1 3D view. 5. Design 1 is designated as the basic design.

The invention provides a heterocyclic compound and a pharmaceutical composition and application thereof, and belongs to the technical field of pharmaceutical chemistry. The series of heterocyclic compounds prepared by the invention have efficient sedative, hypnotic and / or anesthetic effects, can control the state of epilepsy, also have an analgesic effect, and have great significance for clinically preparing drugs with the analgesic effect and drugs with anesthetic, sedative, hypnotic and / or capable of controlling the state of epilepsy. The invention provides a new choice for the medicine which has the effects of anesthesia, sedation and hypnosis and / or can control epilepsy persistence and also has an analgesic effect.

The invention provides a limb fixing frame for the intensive care medicine department, and relates to the field of medical instruments, and the limb fixing frame is characterized by comprising a base, an angle adjusting mechanism and a limb lifting mechanism; the angle adjusting mechanism is installed on the base, and the limb lifting mechanism is installed on the angle adjusting mechanism. The fixing device has the advantages that by arranging the angle adjusting mechanism and the limb lifting mechanism with the buffering function, the problem that a patient is forced to keep a stiff posture due to the fact that a fixing device in the prior art is lack of angle adjustment is solved, the limb angle can be flexibly adjusted according to treatment requirements, stability is kept through a self-locking structure, and the fixing device is convenient to use. Muscle fatigue, spasm and ankylosis can be effectively prevented; meanwhile, by means of the buffering design of the flexible supporting plate and the pressure spring, the comfort degree is remarkably improved, the dysphoria and contradictive emotion of the patient are relieved, sedation management and early rehabilitation of the critical patient are facilitated, and it is guaranteed that treatment and nursing are conducted smoothly.

The utility model relates to the field of medical monitoring and anesthesia, in particular to a nasal end-expiratory carbon dioxide monitoring device for non-intubation general anesthesia, which comprises a detection tube and a disposable nasal cannula, the disposable nasal cannula is detachably communicated with one end of the detection tube, an expiration sensor is mounted on the inner wall of the detection tube and electrically connected with a controller, and the controller is electrically connected with the nasal end-expiratory carbon dioxide monitoring device. The controller is electrically connected with an indicator lamp, the controller and the indicator lamp are installed on the detection tube, and the controller controls the indicator lamp to flicker along with the expiration times of carbon dioxide. The device can effectively monitor end-expiratory carbon dioxide in real time for sedative and analgesic patients with non-intubation and difficult airway anesthesia, can timely and effectively recognize and give an alarm for airway obstruction, and can effectively give an early warning for hypoxia.

A personalized targetable optimal level of sedation is derived through automated real-time analysis of an electroencephalogram (EEG) entropy / variability metric and a cerebrovascular reactivity metric. Ongoing real-time collection is made of both EEG entropy / variability metric values and physiological measurements. Artifact detection and removal on raw signals precedes and derivation of real-time cerebrovascular reactivity metric values from the physiological measurements, and calculation of a first and second summary metrics of first and second respective sample sets of the EEG entropy / variability metric values and cerebrovascular reactivity metric values collected in a given period of time. More data points are curated over longer windows of time, and for each such window, are binned by the first summary metric. A curve is fitted to the grouped data points, and a point of lowest cerebrovascular reactivity metric value on the curve is identified, whose EEG entropy / variability metric value denotes the personalized targetable optimal level of sedation.

The invention relates to a pharmaceutical composition of an etomidate derivative and cyclopofol, and a pharmaceutical composition containing the etomidate derivative and the cyclopofol. Use of the pharmaceutical combination or pharmaceutical composition for anesthesia, sedation and / or hypnosis of animals or humans. Compared with independent administration of the etomidate derivative or the cyclopofol and combined administration of the etomidate and the cyclopofol, the pharmaceutical composition or the pharmaceutical composition shows an excellent synergistic effect, and the waking time after anesthesia withdrawal is remarkably improved.

The invention provides a heterocyclic compound and application thereof, and belongs to the technical field of medicinal chemistry. The structure of the heterocyclic compound is shown as a formula II. The compound provided by the invention has efficient sedation, hypnosis and / or anesthesia effects, can control the state of epilepsy, also has an analgesic effect, and has great significance for clinically preparing drugs with the analgesic effect, drugs with anesthesia, sedation and hypnosis effects and / or drugs capable of controlling the state of epilepsy. The invention provides a new choice for the medicine which has the effects of anesthesia, sedation and hypnosis and / or can control epilepsy persistence and also has an analgesic effect.

This invention provides a treatment for patients with developmental and epileptic encephalopathy (DEE) that addresses behavioral problems in addition to seizures, without causing undesirable side effects such as somnolence, lethargy, withdrawal, and sedation. [Solution] A method is provided for treating behavioral problems and seizures in a subject having DEE, comprising administering an effective amount of cannabidiol (CBD) transdermally to the subject, wherein the behavioral problems are treated in the subject.

The present invention relates to a quantitative electroencephalogram (QEEG) monitor and system capable of monitoring and displaying simultaneously neuropathological characteristic and activity of both sides of a subject's brain. The methods include various indices and examination of differences in these indices by which neurophysiological conditions or problems can be identified and treated. These methods, and the systems and devices using these methods preferably can be used for identifying these neurophysiological conditions or brain dysfunction with monitors and methods for seizure detection, for sedation monitoring, for anesthesia monitoring, and the like. These bilateral brain monitoring methods and systems, and the devices using these methods can be used by individuals or clinicians with little or no training in signal analysis or processing. These bilateral monitoring methods can also be used in a range of applications.

The invention relates to the crossing field of anesthetic medicine and artificial intelligence, and discloses a remazolam anesthetic dosage AI prediction system, which comprises a data acquisition module, a data processing module, a data processing module and a data processing module, and is characterized in that the data acquisition module is used for acquiring multi-dimensional clinical data of a target patient; the feature engineering module is used for generating a standardized feature data set based on the multi-dimensional clinical data; the improved StochDiff time sequence prediction module is used for outputting an initial individualized drug delivery scheme of the remazolam and prediction distribution of vital signs and sedation depth of a patient after drug delivery through a pre-trained improved StochDiff time sequence prediction model based on the standardized feature data set; the dose dynamic correction module is used for carrying out online dynamic correction on the initial individualized administration scheme based on patient data collected in real time in an operation and updating administration parameters in real time; and the safety early warning module is used for realizing pre-grading early warning of adverse anesthesia events based on a model prediction result and real-time data in an operation. Therefore, individualized precise administration and anesthesia safety guarantee are realized.

The present application discloses a kind of drug composition treatment psychotropic disease and the use in pruritus. Specifically, the present application discloses the use of compound beta01 with the following formula structure, or its pharmaceutically acceptable salt and antipsychotic drug composition for preparing the drug for treating psychotropic disease and pruritus.The compound beta01 provided by the present application will not cause side effects such as anxiety and sedation, and is particularly friendly to the population who suffer from anxiety and sedation caused by taking drugs.